Payment overview · 2025
General Payments
$70.66
3 reported records · 1 companies
Healthcare provider profile · identity verified
Scott L Kosfeld, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOLMES BEACH, FL · NPI 1356336580
Verified facts
What the public records show
CMS Open Payments records show Scott L Kosfeld, MD received $70.66 in general payments during 2025 across 3 reported records.
GE HEALTHCARE accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $70.66 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.66 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 336 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 85 |
| Lisinopril | Lisinopril | 251 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 50 |
| Losartan Potassium | Losartan Potassium | 141 | 40 |
| Prednisone | Prednisone | 137 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 32 |
| Omeprazole | Omeprazole | 106 | 32 |
| Gabapentin | Gabapentin | 105 | 30 |
| Mirtazapine | Mirtazapine | 104 | 26 |
| Metformin Hcl | Metformin Hcl | 100 | 28 |
| Eliquis | Apixaban | 94 | 26 |
| Simvastatin | Simvastatin | 88 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 38 |
| Meloxicam | Meloxicam | 79 | 31 |
| Furosemide | Furosemide | 73 | 30 |
| Alprazolam | Alprazolam | 71 | 17 |
| Bupropion Xl | Bupropion Hcl | 67 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Clonazepam | Clonazepam | 63 | 16 |
| Xarelto | Rivaroxaban | 63 | 12 |
| Lorazepam | Lorazepam | 60 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 23 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 15 |
| Famotidine | Famotidine | 49 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 19 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 46 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 27 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 13 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Carvedilol | Carvedilol | 36 | 15 |
| Cephalexin | Cephalexin | 35 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 12 |
| Cefuroxime | Cefuroxime Axetil | 33 | 27 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | 12 |
| Ozempic | Semaglutide | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 12 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Finasteride | Finasteride | 29 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 17 |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | 11 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.66 · 3 records | GE HEALTHCARE | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error